Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
Application Status
This application is a 371 of PCT/US 2021/061860, filed on 05/25/2023.
Claims 1-20 are currently pending in this patent application.
In response to a previous Office action, a Final Rejection Office action (mailed on 07/07/2026), Applicants filed a response and an amendment on October 06, 2026, is acknowledged.
The Examiner is also acknowledged the filing of Affidavit/Declaration under 37 CFR 1.132.
A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicants’ submission filed on 10/06/2026 has been entered.
Applicants' arguments filed on October 06, 2026, have been fully considered and are deemed persuasive to overcome some of the rejections previously applied. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn.
Claims 1-20 are present for examination.
Priority
Acknowledgement is made of applicants claim for priority of US Provisional applications 63/120,997, filed on 12/03/2020, and 63/196,509 filed on 06/03/2020.
New-Information Disclosure Statement
The information disclosure statement (IDS) submitted on 10/06/2026 is acknowledged. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is considered by the examiner. The signed copy of IDS is enclosed herewith.
New-Claim Rejections - 35 USC § 112(b), or Second Paragraph
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 1-20 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
Claim 1 is indefinite and vague in the recitation of “modified bacterial strain”, which is confusing and unclear as to the scope of the yeast cell that is encompassed. The metes and bounds of the term “modified” are not clear to the Examiner. It is not clear whether said phrase modified meant mutation of bacteria strain, expression of the exogenous genes encoding proteins or modification of the gene in the chromosomal DNA in said bacterial strain, rendering the metes and bounds of the term unclear. The Examiner requests clarification as per the specification. Clarification is required.
Maintained-Claim Rejections - 35 USC § 101
35 U.S.C. 101 reads as follows:
Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefore, subject to the conditions and requirements of this title.
The claimed invention is directed to a naturally occurring nucleic acid or fragment thereof, whether isolated or not, that is not patent-eligible pursuant to the Supreme Court decision in Association for Molecular Pathology v. Myriad Genetics, Inc., -- U.S. -- (June 13, 2013).
The previous rejection of Claims 1-20 under 35 U.S.C. 101 because the claimed invention is not directed to patent eligible subject matter, is maintained. This rejection has been discussed at length in the previous Office Action, and the rejection is maintained as discussed previously and for the following reasons.
The instant rejection is issued because of recent "Guidance for Determining Subject Matter Eligibility Of Claims Reciting Or Involving Laws of Nature, Natural Phenomena, & Natural Products", currently accessible from <http://www.uspto.gov/patents/law/exam/myriad-mayo_guidance.pdf>.
In the instant case, when a claim is determined to recite or involve one or more judicial exceptions, the key inquiry becomes whether the claim as a whole recites something significantly different than the judicial exception. The Guidance provides weighing factors for determining whether a claim recites something that is significantly different than the judicial exception. If the totality of the relevant factors weighs toward eligibility, the claim qualifies as eligible subject matter. However, if the totality of the relevant factors weighs against eligibility, the claim should be rejected.
Based upon consideration of all of the relevant factors with respect to the claims as a whole, the factors weigh against something that is significantly different than a law or product of nature and therefore the claims do not qualify as eligible subject matter. The rationale for this determination is explained below:
Claim 1 is drawn to under Broadest Reasonable Interpretation (BRI) - An isolated modified bacterial strain Thiomonas isabelensis (ECOAUO 1), which has been designated Accession number NRRL No. B-67995, deposited in accordance with the Budapest Treaty at the Agricultural Research Service Culture Collection (USDA, ARS,1815 North University Street, Peoria, IL, 61064) on November 13, 2020.
The word “modified” does not add anything to a bacterial strain Thiomonas isabelensis (ECOAUO 1) structure, which reads on naturally occurring microorganism, unless provides detailed description of the modification, such as mutation of the DNA of said microbial strain such that the modified strain is structurally different than the unmodified strain or any other form of modification.
Given the broadest reasonable interpretation (BRI), the claimed “An isolated modified bacterial strain Thiomonas isabelensis (ECOAUO 1), which has been designated Accession number NRRL No. B-67995, deposited in accordance with the Budapest Treaty at the Agricultural Research Service Culture Collection (USDA, ARS,1815 North University Street, Peoria, IL, 61064) on November 13, 2020, is to be a product/Law of nature. To be eligible, the claimed product is not markedly different in structure from a naturally occurring bacterial strain, In this case, the recited modified bacterial strain Thiomonas isabelensis (ECOAUO 1) is not markedly different from naturally occurring bacterial strain. See Association for Molecular Pathology v. Myriad
PNG
media_image1.png
1
1
media_image1.png
Greyscale
Genetics Inc. 106 USPQ2d 1972 (U.S. Supreme Court 2013). As such, the claimed recited modified bacterial strain Thiomonas isabelensis (ECOAUO 1), is not markedly different in structure from naturally occurring bacterial strain, and thus, the claimed “bacterial strain Thiomonas isabelensis (ECOAUO 1) is not patent eligible subject matter.
The claim(s) does/do not include additional elements in terms of the structure and function, but the claim strain only recite functional properties, that are not sufficient to amount to significantly more than the judicial exception because of the following analysis:
Step 1) Are the claims directed to a process, machine, manufacture or composition of matter?
Yes, the claims are drawn to a composition of matter or manufacture (a product).
Step 2a, Prong 1) Does the claim recite an Abstract Idea, Law of Nature or Natural Phenomenon?
Yes, the claim 1 is drawn to a Natural Phenomenon and Law of Nature, bacterial strain Thiomonas isabelensis (ECOAUO 1) would meet the defined claim and render it non-patent eligible.
Step 2a, Prong 2) Does the claim recite additional elements that integrate the Judicial Exception into a Practical Application?
The answer is No. the claimed bacterial strain Thiomonas isabelensis (ECOAUO 1 doesn’t improve any technology or technical field, apply or use the JE to effect to a particular application or apply/use the JE in some other meaningful way.
Step 2B) Does the claim recite additional elements that amount to significantly more than the Judicial Exception?
The answer is No, therefore, the recited bacterial strain Thiomonas isabelensis (ECOAUO 1) is not patent eligible.
Claims 2-20 are also not patent eligible for the same reason as discussed above for claim 1.
Arguments: Applicants argue that the isolated, modified bacterial strain modified from wild-type by exhibiting increased in production of one or more enzymes selected from the group consisting of nitrate reductase, ligninases, cellulase, chitinase, and urease, the increased production of the one or more enzymes evidenced by one or more tests on substrates inoculated with the isolated, modified bacterial strain selected from the group consisting of photon spectra, fire assay, percent cyanide recoverable, preg-rob factor, and sulfide percent. that they provides the data in the accompanying Subject Matter Eligibility Declaration (SMED) to definitively show that the claimed recited bacterial strain Thiomonas isabelensis (ECOAUO 1), is indeed markedly different in structure from naturally occurring bacterial strain. As should be apparent from the data in the SMED, which supports and enhances the data presented in the original application was filed, the microbial strain recited in claim 1 possesses markedly higher amounts of important amino acids, which in turn contributes to the increase seen in gold recovery by the subject microbial strain vs. wild type.
Therefore, Applicant respectfully maintains that the claimed recited modified bacterial strain Thiomonas isabelensis (ECOAUO 1), is indeed markedly different in structure from naturally occurring wild type bacterial strain Thiomonas isabelensis, and therefore claim 1, as amended, recites a patent eligible subject matter.
Response: Applicants’ argue in a lengthy statement in the Remarks, and in the Declaration have been fully considered but are not deemed persuasive to overcome the rejection under 35 USC 101 because Applicants failed to distinguish the claimed modified Thiomonas isabelensis ECOAU001 strain is different from the natural counterpart in a side-by-side comparison with three different test conditions, is in a side-by-side comparison in terms of structure and function, and culture conditions. Since, 101 issue is solely pertaining to structure of the bacterial strain Thiomonas isabelensis ECOAU001, and the Examiner would not respond to functional data.
The word “modified” recited in the amended claim 1 does not add anything to the bacterial strain Thiomonas isabelensis (ECOAUO 1) structure, which reads on a naturally occurring microorganism, unless provides detailed description of the modification, such as mutation of the DNA of said microbial strain and/or shows that the modified strain is structurally different than the unmodified strain or any other form of modification. Applicants also are advised to provide clearer information as per specification and provide the evidential information regarding how the modification was performed and its effect on the structure and function correlation with a side-by-side experimental evidential comparison between modified and unmodified strain as per Rule 105. Of USPTO (see, MPEP).
Regarding the Affidavit/Declaration as SMED, the evidential supports all the studies for the functional studies without structural evidence between the claimed modified and unmodified bacterial strain and without side-by-side comparison or by showing with sequencing of the DNA between modified and unmodified strain under identical conditions and thus, the Examiner would not consider the SMED as a proper SMED and is not convincing to overcome the rejection.
Since, Applicants failed to prove that claimed strain is structurally different than natural one, and thus, the rejection is maintained.
Conclusion
Claims 1-20 stand/are rejected.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to IQBAL H CHOWDHURY whose telephone number is (571)272-8137. The examiner can normally be reached on M-F from 9:00 AM-5:00 PM.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Manjunath N. Rao, can be reached on 571-272-0939. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).
Iqbal H. Chowdhury, Primary Examiner
Art Unit 1656 (Recombinant Enzymes and Protein Crystallography)
US Patent and Trademark Office (USPTO)
Ph. (571)-272-8137 and Fax (571)-273-8137
/IQBAL H CHOWDHURY/
Primary Examiner, Art Unit 1656